Weight loss drug could be a gamechanger for cardiovascular disease
Drug Discovery World
MAY 14, 2024
Semaglutide (the active ingredient in Wegovy and Ozempic) can produce clinically meaningful weight loss and delivers significant cardiovascular benefits, according to two studies presented at the European Congress on Obesity (ECO). The studies are based on the Semaglutide and Cardiovascular Outcomes (SELECT) trial, the largest and longest clinical trial of the effects of semaglutide on weight in over 17,000 adults.
Let's personalize your content